PCSK9 and familial hyperaldosteronism: Our preliminary findings suggest a possible positive role of this novel lipid-lowering strategy on vascular homeostasis; however, a randomized controlled prospective trial is required to evaluate the effect of PCSK9-i therapy on these pathways in a large cohort of FH subjects.